Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: A cross-sectional study
暂无分享，去创建一个
A. Giacomelli | S. Antinori | M. Galli | L. Milazzo | G. Rizzardini | A. Ridolfo | L. Oreni | D. Mileto | A. Rizzo | A. Torre | M. Schiuma | Matteo Siano | L. Pezzati | F. Conti | Alice Covizzi | Matteo Passerini | M. Piscaglia | C. Bassoli | G. Gagliardi
[1] A. Giacomelli,et al. Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] A. Giacomelli,et al. Is COVID-19 severity associated with anti-spike antibody duration? Data from the ARCOVID prospective observational study , 2021, Journal of Infection.
[3] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[4] A. Hoerauf,et al. Performance of the COVID19SEROSpeed IgM/IgG Rapid Test, an Immunochromatographic Assay for the Diagnosis of SARS-CoV-2 Infection: a Multicenter European Study , 2020, Journal of Clinical Microbiology.
[5] A. Giacomelli,et al. Seroprevalence of SARS-CoV-2 significantly varies with age: Preliminary results from a mass population screening , 2020, Journal of Infection.
[6] A. Giacomelli,et al. Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d’Adda, Italy , 2020, PloS one.
[7] J. Sodroski,et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike , 2020, Nature.
[8] M. Hernán,et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study , 2020, The Lancet.